Effect of pregnancy on the pharmacokinetics of paclitaxel: a case report.
Breast cancer during pregnancy is increasingly common as women delay childbearing until later in life. Safe administration of adjuvant chemotherapy during pregnancy has been reported. Physiologic and metabolic changes during pregnancy could alter the pharmacokinetics of these agents. This is a pilot study to prospectively study the pharmacokinetics of chemotherapeutic agents during pregnancy. Herein, we report the initial results with paclitaxel in the first patient.
Lycette
Jennifer L
JL
Hematology and Medical Oncology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. lycettej@comcast.net
Dul
Carrie L
CL
Munar
Myrna
M
Belle
Donna
D
Chui
Stephen Y
SY
Koop
Dennis R
DR
Nichols
Craig R
CR
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D019540:Area Under Curve; D001943:Breast Neoplasms / Q000188:drug therapy*; D044584:Carcinoma, Ductal / Q000188:drug therapy*; D005260:Female; D006207:Half-Life; D006801:Humans; D050498:Live Birth; D017239:Paclitaxel / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D016896:Treatment Outcome; D014427:Twins
D000970:Antineoplastic Agents; D017239:Paclitaxel